Oculus Innovative Sciences Announces New Regulatory Approvals for Microcyn(R)-Based Antiseptic Products in Panama and El

Oculus Innovative Sciences Announces New Regulatory Approvals for
Microcyn(R)-Based Antiseptic Products in Panama and El Salvador

PETALUMA, Calif., May 1, 2013 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences,
Inc. (Nasdaq:OCLS) a global healthcare company that designs, manufactures and
markets prescription and non-prescription products in over 20 countries, today
announced new regulatory approvals for Microcyn®-based antiseptic products,
under the brand name Microdacyn®, in Panama and El Salvador.

Bruce Thornton, executive vice president of Oculus said: "The growth of our
Microcyn-based product portfolio and expansion of our international footprint
are indeed synergistic. Working in close collaboration with strong global
partners, such as More Pharma, we continue—week after week—to announce new
regulatory approvals, new products and new territories to be served. At the
end of the day, an expanded global population benefits from the availability
of the Microcyn technology."

Oculus' Latin American partner, More Pharma, intends to begin
commercialization of these new antiseptic products in both countries in the
summer of 2013.

Guillermo Ibarra, More Pharma's CEO said, "Since we acquired the license to
the Microcyn-based products in August of 2012, our customers have come to
recognize the Microdacyn brand as a highly efficacious product for both
advanced wound care and dermatology, allowing us to build upon Oculus'
established success in Mexico while we further expand these product offerings
into the other countries of South and Central America, and the Caribbean."

About Oculus Innovative Sciences

Oculus Innovative Science is a global healthcare company that designs,
manufactures and markets prescription and non-prescription products in over 20
countries. The company's products are used to treat patients in
surgical/advanced wound management, dermatology, women's health and animal
health; addressing the unmet medical needs of these markets—while raising the
standard of patient care and lowering overall healthcare costs. The company's
headquarters are in Petaluma, California, with manufacturing operations in the
United States and Latin America. More information can be found at
www.oculusis.com.

About More Pharma

Founded in 2007, More Pharma is a pharmaceutical company with strong growth
performance and a team of more than 300 people. The company has a talented
sales and marketing team with significant prior experience with large
international pharmaceutical companies. They have ample funding and support by
their renowned financial sponsors, Southern Cross Group and Evercore, both of
which manage more than $1 billion of venture funds. The company is dedicated
to finding solutions to healthcare challenges via product development,
in-licensing and product acquisitions.With headquarters in Mexico City, More
Pharma has a presence in Mexico, Latin America and the Caribbean.More
information can be found at www.morepharmacorp.com/eng/compania.php

Forward-Looking Statements

Except for historical information herein,matters set forth in this press
release are forward-looking within the meaning of the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995, including statements
about the Company's commercial and technology progress and futurefinancial
performance. These forward-looking statements are identified by the use of
words such as "growth," "expansion" and"build,"among others. Forward-looking
statements in this press release are subject to certain risks and
uncertainties inherent in the Company's business that could cause actual
results to vary, includingsuchrisks thatregulatory clinical and guideline
developments may change,scientific data may not be sufficient to meet
regulatory standards or receipt of required regulatory clearances or
approvals,clinical results may not be replicated in actual patient
settings,protection offered bythe Company'spatents and patent applications
may be challenged, invalidated or circumvented by its competitors,the
available market fortheCompany'sproducts will not be as large as
expected,the Company'sproducts will not be able to penetrate one or more
targeted markets,revenues will not be sufficient to fund further development
and clinical studies, the Company may not meet itsfuture capital needs, and
its ability to obtain additional funding, as well as uncertainties relative to
varying product formulations and a multitude of diverse regulatory and
marketing requirements in different countries and municipalities, and other
risks detailed from time to time in the Company's filings with the Securities
and Exchange Commission including the annual report on Form 10-K for theyear
ended March 31, 2012. Oculus Innovative Sciences disclaims any obligation to
update these forward-looking statements except as required by law.

Oculus and Microcyn Technology are trademarks or registered trademarks of
Oculus Innovative Sciences, Inc. All other trademarks and service marks are
the property of their respective owners.

CONTACT: Media and Investor Contact:
        
         Oculus Innovative Sciences, Inc.
         Dan McFadden
         VP of Public and Investor Relations
         (425) 753-2105
 
Press spacebar to pause and continue. Press esc to stop.